Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma - Supplementary Table 1

Background: We aimed to evaluate the effect of sarcopenia on survival in head and neck squamous

cell carcinoma patients treated with chemoradiotherapy. Materials & methods: Disease-free survival and

overall survival were compared according to cervical computed tomography for radiotherapy in 123

sarcopenic and non-sarcopenic patients with locally advanced head and neck squamous cell carcinoma

treated with chemoradiotherapy with weekly cisplatin. Results: In multivariate analyses, pretreatment

sarcopenia was associated with lower disease-free survival (hazard ratio: 2.60; 95% CI: 1.38–4.87; p = 0.003)

and overall survival (hazard ratio: 2.86; 95% CI: 1.40–5.85; p = 0.004). Sarcopenic patients experienced more

frequent radiotherapy-related toxicities and platinum-related side effects than non-sarcopenic patients.

Conclusion: Sarcopenia could be a potential biomarker to predict prognosis and treatment toxicity in head

and neck squamous cell carcinoma.

背景：本研究旨在评估肌少症（sarcopenia）对接受放化疗（chemoradiotherapy）治疗的头颈部鳞状细胞癌（head and neck squamous cell carcinoma）患者生存结局的影响。
材料与方法：本研究纳入123例接受每周顺铂（cisplatin）方案放化疗的局部晚期头颈部鳞状细胞癌患者，根据放疗前颈部计算机断层扫描（computed tomography）结果将其分为肌少症组与非肌少症组，比较两组的无病生存期（disease-free survival）与总生存期（overall survival）。
结果：多因素分析显示，治疗前肌少症与更差的无病生存期（风险比（hazard ratio）：2.60；95%置信区间（95% CI）：1.38~4.87；P=0.003）及总生存期（风险比：2.86；95%置信区间：1.40~5.85；P=0.004）显著相关。与非肌少症患者相比，肌少症患者更易出现放疗相关毒性反应及铂类相关不良反应。
结论：肌少症有望成为预测头颈部鳞状细胞癌患者预后及治疗毒性反应的潜在生物标志物。